In recent years, there has been great interest in exploiting the biochemical modification of ,-lactam compounds. One area which so far has been less than fruitful is the development of penems. Although many, including Sch 29,482, have been synthesized (2, 3, 7, 9) , not one has been fully developed. FCE 22101 (Fig. 1) is a new penem having the formula sodium (5R, 6S, 8R)-6-hydroxyethyl-2-carbamoyloxymethyl-2-penem-3-carboxylate and differs from Sch 29,482, which has an ethylthio group in the 2 position (6). In this study, we compared FCE 22101 with other 3-lactams against a wide range of recent clinical isolates and also against strains known to be resistant to certain of these agents. The effect of serum on the activity of the compound was also studied.
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MATERIALS AND METHODS Strains and antimicrobial agents. Of the 472 strains examined in this study, 449 were recent clinical isolates from this hospital and are listed in Table 1 according to strain and number. The remaining 23 were well characterized ,B-lactamase producers and other resistant strains donated from various sources. The antibiotics, of known potency, were obtained from the following pharmaceutical companies: FCE 22101 from Farmitalia Carlo Erba, Milan, Italy; ceftriaxone from Roche Products, Welwyn Garden City, England; moxalactam from Lilly Research Centre, Windlesham, England; imipenem (formerly imipemide, N-formimidoyl thienamycin, or MK 0787) from Merck Sharp & Dohme, Hoddesdon, England; cefuroxime and ceftazidime from Glaxo Research, Greenford, England; carbenicillin, penicillin, and ampicillin from Beecham Research Laboratories, Brentford, England.
Methods. The susceptibilities of the strains to the compounds were studied by a routine agar plate dilution method with Iso-Sensitest agar (pH 7.2) (Oxoid Ltd., Basingstoke, England), which was supplemented as follows: 5% whole horse blood to support growth of streptococci (including S. pneumoniae); a Levinthal preparation (5) to support the growth of Haemophilus influenzae; a Mast Laboratories Ltd. (Liverpool, England) SAF (sulfonamide antagonist-free) medium supplemented with 5% horse blood to support the growth of Neisseria gonorrhoeae. For the Bacteroides spp., Wilkins-Chalgren (Oxoid) agar was used.
Inocula were prepared as follows. For all strains except streptococci (including Streptococcus pneumoniae), Neisseria gonorrhoeae, Haemophilus influenzae, and Bacteroides spp., the organisms were grown overnight in nutrient broth yielding a viable count of about 109 CFU/ml. Streptococci (including Lancefield group D) were grown in Todd-Hewitt broth; Haemophilus influenzae, Streptococcus pneumoniae, and Neisseria gonorrhoeae were grown in Levinthal broth; and Bacteroides fragilis was grown in Wilkins-Chalgren broth, each giving comparable viable counts.
WISE, ANDREWS, AND DANKS
The inocula were obtained by transferring 1 pl of an undiluted or a 1:100 dilution of the overnight culture to the surface of the antibiotic-containing medium by a Denley multipoint inoculating device (Denley-Tech Ltd., Billingshurst, England). The final inocula on the plates were therefore 10' and 106 CFU/ml. Incubation was for 24 h in air at 37°C (except for Haemophilus influenzae and Neisseria gonorrhoeae when 10%/ CO2 was added). The dilution, inoculation, and incubation of the Bacteroides spp. were performed in an anaero- pooled human serum and decreasing concentrations of FCE 22101. The final inoculum was about 105 CFU/ml. After 24 h of incubation at 37°C in air, the MIC was defined as the concentration of FCE 22101 at which there was no visible growth. The broths were then subcultured (0.01 ml transferred onto nutrient agar) and incubated for an additional 24 h. The minimum bactericidal concentration (MBC) of FCE 22101 was defined as the lowest concentration in the original broth at which there was no growth after subculture. This was calculated to be equivalent to a lethality rate of 99.9%o.
The protein binding of FCE 22101 in human serum was estimated by an ultrafiltration technique (4), using an Amicon (Amicon Corp., Lexington, Mass.) Centriflo cone with a molecular weight exclusion of 50,000. The concentrations of FCE 22101 used were 5, 100, and 200 ,ug/ml. The ultrafiltrate (after a pH adjustment with CO2 gas) was assayed by a microbiological technique against standards prepared in phosphate-buffered saline, pH 6.5 (the pH of the ultrafiltrate after the addition of C02). The indicator organism was a strain of Staphylococcus aureus F208, and the medium was Oxoid antibiotic medium no. 1.
RESULTS
The results obtained for 429 isolates tested at an inoculum of 104 CFU/ml are summarized in Against Acinetobacter anitratum, FCE 22101 and imipenem displayed high activity. Against Pseudomonas aeruginosa, the activity of FCE 22101 was comparable to that of carbenicillin and was 64-fold less than that of imipenem. Table 2 shows the susceptibilities of nine known P-lactamase-producing strains of Enterobacteriaceae, at two inocula, classified by the method of Richmond and Sykes (8). Cefuroxime was not active against groups I and IV strains, and ceftriaxone was not active against the group I strains. The other agents were active and had little effect when the inoculum was increased from 104 to 106 CFU/ml, suggesting that littlelactamase hydrolysis was occurring. Against Staphylococcus aureus, FCE 22101 showed activity similar to that of imipenem. The mode MIC of FCE 22101 against the 10 methicillin-resistant strains was 0.25 ,.g/ml (range, 0.12 to 2 ,ug/ml); the mode MIC of the 20 methicillinsusceptible strains was 0.12 ,ug/ml (range, 0.06 to 0.5 ,ug/ml). Similar results were obtained with imipenem, but with the other antimicrobial agents, the mode MIC for the methicillin-resistant strains was markedly higher than that for the methicillin-susceptible strains (e.g., ceftriaxone, methicillin-resistant mode MIC of 32 ,ug/ml; methicillin-susceptible mode MIC of 4 ,ug/ml). An increase in inoculum resulted in at most a twofold decrease in susceptibility of all strains to FCE 22101.
All the compounds tested, with the exception of moxalactam, showed high activities against Streptococcus pneumoniae. One strain showing reduced susceptibility to penicillin (MIC, 0.12 Lg/ml) was susceptible to 0.25 ,ug of FCE 22101 per ml, 0.03 ,ug of imipenem per ml, and 2 ,ug of ceftazidime per ml.
In all, five strains of Lancefield group A, 4 strains of Lancefield group B, and 10 strains of
Lancefield group D streptococci were tested (not shown in Table 1 ). The group A streptococci were all susceptible to between 0.06 and 0.12 ,ug of FCE 22101 per ml. The group B streptococci were susceptible to 0.25 ,ug or less of FCE 22101 per ml. The group D streptococci were inhibited by between 1 and 4 ,ug of FCE 22101 per ml and by 0.5 to 1.0 ,ug of imipenem per ml, but the other cephalosporins (including moxalactam) had no activity (mode MIC, >128 ,ug/ml). The 11 ,B-lactamase-producing strains of Haemophilus influenzae were as susceptible to FCE 22101 as were the non-p-lactamase producers.
Also included in the strains tested were five which were presumed to have a permeability barrier to ampicillin (i.e., an ampicillin MIC of -0.5 ,ug/ml, with little or no increase in MIC when the inoculum was increased to 106 CFU). These strains were all susceptible to 0.5 to 1 xLg of FCE 22101 per ml, whereas they showed a decrease in susceptibility to moxalactam (MIC, IN VITRO ACTIVITY OF FCE 22101 913 0.5 to 2 Fg/ml), ceftiaxone (MIC, 0.04 to 0.06 jig/ml), ceftazidime (MIC, 0.5 to 1 ,ug/ml), and cefuroxime (MIC, 1 to 16 jig/ml). Imipenem, however, was as active against such strains as against those not having this presumed permeability barrier.
Ceftriaxone was the agent most active against the strains of Neisseria gonorrhoeae tested. FCE 22101 was as active as cefuroxime and imipenem, and the 14 P-lactamase-producing strains were as susceptible as the non-p-lactamase-producing strains.
Of the 29 strains of Bacteroides spp. tested, 25 were of B. fragilis, 2 were of B. thetaiotaomicron, and 1 each were of B. ovatus and B. vulgatus. All were highly susceptible to FCE 22101. One known cefoxitin-resistant (MIC, >64 ,ug/ml) strain of B. thetaiotaomicron was highly resistant to all agents (MIC, .128 pug/ml), except to FCE 22101 and imipenem, to which it was susceptible at 0.5 and 8 jxg/ml, respectively. The strains of B. ovatus and B. vulgatus were as susceptible as the other strains to FCE 22101.
In Table 3 , the effect of serum on the MICs and MBCs is shown. There was little difference between the MICs and MBCs except for one strain of Staphylococcus aureus (methicillin susceptible), when in the absence of serum there was a 32-fold difference, and for one strain of Proteus mirabilis, when there was an >8-fold difference. Generally, serum had little effect on the MICs or MBCs. The mean human serum protein binding of FCE 22101 was 40.6% and varied little with the concentration studied (from 40.0o for 5 pLg/ml to 35.5% for 200 ,ug/ml). DISCUSSION FCE 22101, a penem derivative, exhibits a number of differences when compared with other broad-spectrum P-lactams, especially the cephalosporins. Although the drug is somewhat less active against members of the Enterobacteriaceae than the recently introduced compounds, the narrow range of susceptibilities to FCE 22101 is noteworthy, since these other agents often show a more marked range of susceptibility (e.g., ceftriaxone, 0.015 to 5 ,g/ml). It could therefore be said that FCE 22101 is more predictable in its degree of activity.
FCE 22101 appears to be resistant to the wide range of characterized P-lactamases tested. In particular, it is also active against the clinically important P-lactamase-producing strains of
Haemophilus influenzae and Neisseria gonorrhoeae. In addition to appearing to be resistant to the P-lactamases of the Bacteroides spp., it is also extremely active against these strains: the 50% MIC of FCE 22101 being about 16-fold (6) . Animal studies show that in mice 47% of the ester FCE 22891 and 32% of FCE 22553 are orally absorbed.
